Answers are grounded in this paper and cite their sources.
Demonstrates equivalent survival and improved tolerability with gemcitabine and cisplatin versus MVAC in advanced bladder cancer, supporting a new standard of care.
GC provides a similar survival advantage to MVAC with a better safety profile and tolerability. This better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.
No takes yet. Share an insight, caveat, or question.
Maase et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: